share_log

微芯生物(688321.SH):西达本胺临床试验申请获得受理

Shenzhen Chipscreen Biosciences (688321.SH): The clinical trial application for Sidabonan has been accepted.

Gelonghui Finance ·  Nov 27 17:55

On November 27, Ge Longhui (688321.SH) announced that it recently received the “Notice of Acceptance” for registered clinical trials of domestically produced drugs issued by the Drug Evaluation Center of the State Drug Administration, and the clinical trial application for sidabenamide was accepted by the Drug Evaluation Center of the State Drug Administration. Sidabendamide (Chidamide; trade name “Epidaza”), a national class 1 original innovative drug, is a new molecular physical drug discovered exclusively by the company, with a novel mechanism. As the only oral subtype-selective histone deacetylase (HDAC) inhibitor in the field, sidabendamide has a reactivating effect on the tumor-suppressing immune microenvironment. It can be used alone or in combination with other drugs to solve major diseases such as malignant tumors that seriously threaten human health, and has broad potential application prospects.

Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more
    Write a comment